Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

58364 1487845784HCLSReviewSingaporeFeb2017.pdf
Energy Boardroom

Can payers get to 'rational' hep C drug prices without a price war?

08.05.2014 / Fierce Pharma

Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers Squibb have treatments on the market, Gilead Sciences will have to back off its $84,000-per-treatment-course sticker price. The reality could be a little better–and a little worse–than that.

Cover_HCLS_Singapore LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: